Trials / Completed
CompletedNCT02371967
A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
A Prospective Observational Study of Erivedge® Treatment, Effectiveness, and Safety Outcomes in Patients With Advanced Basal Cell Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, observational, cohort study is designed to assess the effectiveness and safety outcomes of vismodegib and to assess actual day-to-day disease and participant management by the physician.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vismodegib | Vismodegib therapy will be given in compliance with the physician's standard practice as per local label. |
Timeline
- Start date
- 2015-04-08
- Primary completion
- 2020-08-19
- Completion
- 2020-08-19
- First posted
- 2015-02-26
- Last updated
- 2020-10-09
Locations
4 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02371967. Inclusion in this directory is not an endorsement.